GrpE-like 1-engineered synovial mesenchymal stromal cell exosomes: Mechanistic and translational priorities in osteoarthritis

Abstract

Osteoarthritis (OA) remains a highly prevalent degenerative joint disorder for which truly disease-modifying therapies are still lacking. Accumulating evidence positions mitochondrial dysfunction and impaired mitochondrial quality control as central drivers of chondrocyte failure, extracellular matrix breakdown, and inflammation amplification. Mitophagy—particularly the phosphatase and tensin homolog-induced kinase 1 (PINK1)/Parkin axis—has therefore emerged as an attractive, mechanistically grounded intervention point. In this context, synovial mesenchymal stem cell-derived exosomes (SMSC-Exos) represent a compelling cell-free platform capable of delivering functional biomolecules into inflamed cartilage microenvironments. Recent experimental work demonstrates that engineering SMSC-Exos to deliver the mitochondrial co-chaperone GrpE-like 1 (GRPEL1) restores chondrocyte proliferative and migratory capacity under interleukin-1β stress, preserves anabolic extracellular matrix markers (collagen type II alpha 1/aggrecan), suppresses catabolic mediators (matrix metalloproteinase 13/A disintegrin and metalloproteinase with thrombospondin motifs 5), and mitigates oxidative damage while enhancing mitophagy signatures. Mechanistically, GRPEL1 directly associates with PINK1, and PINK1 knockdown attenuates the protective phenotype, supporting a GRPEL1-PINK1 coupling model. In vivo, intra-articular administration of GRPEL1-enriched SMSC-Exos improves histological cartilage integrity and mitophagy-related readouts in a rat OA model. Here, we synthesize mechanistic implications, highlight interpretive nuances (e.g., mitophagy activation concurrent with membrane potential recovery), and outline translational priorities, including cargo quantification, mitophagy flux validation, dosing/retention kinetics, manufacturing standardization, and biomarker-driven patient stratification.

Keywords: Cartilage regeneration; Engineered exosomes; GrpE-like 1; Mesenchymal stromal cells; Mitophagy; Mitochondrial homeostasis; Mitochondrial quality control; Osteoarthritis; Phosphatase and tensin homolog-induced kinase 1; Translational therapeutics

Core Tip: Osteoarthritis still lacks reliable disease-modifying therapies. This review highlights an emerging mitochondria-centered strategy in which synovial mesenchymal stem cell-derived exosomes deliver GrpE-like 1 to engage the phosphatase and tensin homolog-induced kinase 1-dependent mitophagy pathway, improving mitochondrial homeostasis and cartilage outcomes across in vitro and in vivo models. We synthesize the mechanistic rationale and delineate the minimal translational checkpoints required for clinical readiness: Flux-based and specificity-anchored causal validation; chemistry, manufacturing, and controls—including a standardized product definition with mechanism-linked potency assays; and intra-articular pharmacokinetics/pharmacodynamics coupled to biomarker-driven patient stratification.